Cellectar Biosciences Inc. Daily Stock Analysis

Daily Stock Analysis, CLRB, Cellectar Biosciences Inc, priceseries

Cellectar Biosciences Inc. Daily Stock Analysis
Stock Information
Open
0.46
Close
0.46
High
0.46
Low
0.44
Previous Close
0.47
Daily Price Gain
-0.01
YTD High
0.73
YTD High Date
Jan 13, 2022
YTD Low
0.44
YTD Low Date
Feb 24, 2022
YTD Price Change
-0.25
YTD Gain
-35.90%
52 Week High
2.12
52 Week High Date
Mar 16, 2021
52 Week Low
0.44
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-1.27
52 Week Gain
-73.69%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 23. 2017
13.80
Feb 23. 2017
22.01
22 Trading Days
59.51%
Link
LONG
Sep 12. 2017
16.20
Sep 20. 2017
17.28
6 Trading Days
6.68%
Link
LONG
Dec 20. 2017
12.30
Jan 4. 2018
13.02
9 Trading Days
5.84%
Link
LONG
Jul 13. 2018
7.40
Jul 17. 2018
10.08
2 Trading Days
36.22%
Link
LONG
Sep 19. 2018
2.42
Oct 3. 2018
3.06
10 Trading Days
26.39%
Link
LONG
Mar 14. 2019
2.16
Mar 21. 2019
2.33
5 Trading Days
7.99%
Link
LONG
Nov 22. 2019
1.56
Dec 18. 2019
2.06
17 Trading Days
32.31%
Link
LONG
Apr 24. 2020
1.46
May 7. 2020
1.65
9 Trading Days
12.76%
Link
LONG
Dec 2. 2020
1.95
Dec 9. 2020
2.05
5 Trading Days
5.13%
Link
LONG
Feb 1. 2021
1.99
Feb 17. 2021
2.21
11 Trading Days
10.89%
Link
Company Information
Stock Symbol
CLRB
Exchange
NasdaqCM
Company URL
http://www.cellectar.com
Company Phone
(608) 441-8120
CEO
James V. Caruso
Headquarters
Wisconsin
Business Address
3301 AGRICULTURE DRIVE, MADISON, WI 53716
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001279704
About

Cellectar BioSciences, Inc. operates as a biopharmaceutical company. It engages developing phospholipid drug conjugates designed to provide cancer targeted delivery of oncologic payloads to cancer stem cells. The company was founded on April 11, 2011 and is headquartered in Madison, WI.

Description

Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, engages in the development of targeted phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. It offers CLR 131, a PDC radiotherapeutic product candidate and is currently being evaluated in a Phase I study for the treatment of relapse or refractory multiple myeloma; CLR 125, a cancer-targeting radiotherapeutic is under pre-clinical investigation for the treatment of micrometastatic disease ; CLR 124, a cancer-targeting positron emission tomography (PET) imaging PDC for the selective detection of tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting NIR-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Madison, Wisconsin.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading